<DOC>
	<DOC>NCT01743729</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and efficacy of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye.</brief_summary>
	<brief_title>A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Willing and able to read, sign and date the informed consent and HIPAA documents Willing and able to comply with all study procedures Be at least 18 years of age Patientreported history of dry eye in both eyes A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period Artificial tear use within the past 30 days Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy Unwilling to avoid wearing contact lenses for 7 days prior to first visit and for the duration of the study Any blood donation or significant loss of blood within 56 days of Visit 1 Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (antiHAV IgM), or organ or bone marrow transplant. Use of any prohibited medications at any time during the study unless otherwise specified Any significant illness that could interfere with study parameters History of laser assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to first visit, and/or any other ocular surgical procedure within 12 months prior to first visit; or any scheduled ocular surgical procedure during the study period. Known history of alcohol and/or drug abuse Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SAR 1118</keyword>
</DOC>